Sphera Funds Management’s Vaxcyte PCVX Stock Holding History

Sphera Funds Management’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-50,000	Closed	-$1.8M	–	125
2025 Q3	$1.8M	Buy	+50,000	New	+$1.66M	0.38%	77
2023 Q2	–	Sell	-90,000	Closed	-$3.37M	–	96
2023 Q1	$3.37M	Buy	+90,000	New	+$3.82M	0.56%	53

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Sphera Funds Management's PCVX Position: Q4 2025 in Review

Sphera Funds Management sold out of Vaxcyte (PCVX) in Q4 2025, closing a stake of 50,000 shares — an estimated $1.8M sold.

Sphera Funds Management first reported a position in PCVX in Q1 2023 and held it in 2 quarters. The position peaked at $3.37M in Q1 2023. 295 funds tracked by Wall St. Rank hold PCVX as of Q4 2025.

Sphera Funds Management reported no remaining Vaxcyte position as of Q4 2025 after selling out during the quarter.
Sphera Funds Management sold 50,000 Vaxcyte shares in Q4 2025, an estimated $1.8M.
Sphera Funds Management first reported a position in Vaxcyte in Q1 2023 and held it in 2 quarters.
Sphera Funds Management's Vaxcyte position peaked at $3.37M in Q1 2023.
295 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2025.

Based on Sphera Funds Management's 13F filing for Q4 2025, filed 17 Feb 2026.